Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label multicenter superiority study of long-acting octreotide injection in acromegaly
CTR20261498Phase 3Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of octreotide in acromegaly, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started May 2026; status: active.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on CTR20261498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261498.